The efficacy of photochemical treatment with amotosalen HCl and ultraviolet a (INTERCEPT) for inactivation of Trypanosoma cruzi in pooled buffy-coat platelets

Transfusion

Volumn 47, Issue 3, 2007, Pages 434-441

  Castro, Emma ^a   Gironés, Nuria ^b   Bueno, José Luis ^b   Carrión, Javier ^b   Lin, Lily ^b   Fresno, Manuel ^b  

^a Centro de Transfusion de Cruz Roja Espanola   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

'INTERCEPT'; AMOTOSALEN; GAMMA INTERFERON RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BLOOD CULTURE; BLOOD SAMPLING; CELL ASSAY; CONTAMINATION; CONTROLLED STUDY; EPIMASTIGOTE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; INSTRUMENTATION; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PARASITOSIS; PHOTOCHEMICAL EFFICIENCY; THROMBOCYTE; THROMBOCYTE TRANSFUSION; TRYPANOSOMA CRUZI; ULTRAVIOLET A RADIATION;

ANIMALS; BLOOD; BLOOD SPECIMEN COLLECTION; CHAGAS DISEASE; LIGHT; MICE; MICE, KNOCKOUT; MODELS, BIOLOGICAL; PLATELET TRANSFUSION; PSORALENS; RECEPTORS, INTERFERON; TRYPANOSOMA CRUZI; ULTRAVIOLET RAYS;

EID: 33847077941     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2007.01133.x     Document Type: Article

References (31)

1. Schmunis GA. Trypanosoma cruzi, the etiologic agent of Chagas' disease: status in the blood supply in endemic and nonendemic countries. Transfusion 1991;31:547-57.
2. Moraes-Souza H, Bordin JO, Bardossy L, et al. Prevention of transfusion-associated Chagas' disease: efficacy of white cell-reduction filters in removing Trypanosoma cruzi from infected blood. Transfusion, 1995;35:723-6.
3. Wendel S. Transfusion-transmitted Chagas' disease. Curr Opin Hematol 1998;5:406-11.
4. Cimo PL, Luper WE, Scouros MA. Transfusion-associated Chagas' disease in Texas: report of a case. Tex Med 1993;89:48-50.
5. Grant IH, Gold JW, Wittner M, et al. Transfusion-associated acute Chagas disease acquired in the United States. Ann Intern Med 1989;111:849-51.
6. Wagner SJ, Robinette D. Evaluation of an automated microbiologic blood culture device for detection of bacteria in platelet components. Transfusion 1998;38:674-9.
7. Corash L. Inactivation of infectious pathogens in labile blood components: meeting the challenge. Transfus Clin Biol 2001;8:138-45.
8. Goodrich RP. The use of riboflavin for the inactivation of pathogens in blood products. Vox Sang 2000;78(Suppl 2):211-5.
9. Mohr H. Methylene blue and thionine in pathogen inactivation of plasma and platelet concentrates. Transfus Apher Sci 2001;25:183-4.
10. Lin L, Hanson CV, Alter HJ, et al. Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light. Transfusion 2005;45:580-90.
11. Lin L, Dikeman R, Molini B, et al. Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria. Transfusion 2004;44:1496-504.
12. Singh Y, Sawyer L, Pinkosky L, et al. Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function. Transfusion 2006;46:1168-77.
13. Eastman RT, Barrett LK, Dupuis K, et al. Leishmania inactivation in human pheresis platelets by a psoralen (amotosalen HCl) and long-wavelength ultraviolet irradiation. Transfusion 2005;45:1459-63.
14. Van Voorhis WC, Barrett LK, Eastman RT, et al. Trypanosoma cruzi inactivation in human platelet concentrates and plasma by a psoralen (amotosalen HCl) and long-wavelength UV. Antimicrob Agents Chemother 2003;47:475-9.
15. Murphy S. Platelets from pooled buffy coats: an update. Transfusion 2005;45:634-9.
16. van Rhenen D, Gulliksson H, Cazenave JP, et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003;101:2426-33.
17. Picker SM, Speer R, Gathof BS. Evaluation of processing characteristics of photochemically treated pooled platelets: target requirements for the INTERCEPT Blood System comply with routine use after process optimization. Transfus Med 2004;14:217-23.
18. Janetzko K, Lin L, Eichler H, et al. Implementation of the INTERCEPT Blood System for Platelets into routine blood bank manufacturing procedures: evaluation of apheresis platelets. Vox Sang 2004;86:239-45.
19. Camargo EP. Growth and differentiation in Trypanosoma cruzi. I. Origin of metacyclic Trypanosomes in liquid media. Rev Inst Med Trop Sao Paulo 1964;12:93-100.
20. Buffet PA, Sulahian A, Garin YJ, et al. Culture microtitration: a sensitive method for quantifying Leishmania infantum in tissues of infected mice. Antimicrob Agents Chemother 1995;39:2167-8.
21. Risso MG, Garbarino GB, Mocetti E, et al. Differential expression of a virulence factor, the trans-sialidase, by the main Trypanosoma cruzi phylogenetic lineages. J Infect Dis 2004;189:2250-9.
22. Brener Z. Therapeutic activity and criterion of cure on mice experimentally infected with Trypanosoma cruzi. Rev Inst Med Trop Sao Paulo 1962;4:389-96.
23. Melmed RS, Leiby DA. Transfusion transmission of Trypanosoma cruzi: are platelets our only concern? Transfusion 2006;43(Suppl):13A.
24. Leon JS, Godsel LM, Wang K, et al. Cardiac myosin autoimmunity in acute Chagas' heart disease. Infect Immun 2001;69:5643-9.
25. Munoz-Fernandez MA, Fernandez MA, Fresno M. Activation of human macrophages for the killing of intracellular Trypanosoma cruzi by TNF-alpha and IFN-gamma through a nitric oxide-dependent mechanism. Immunol Lett 1992;33:35-40.
26. Holscher C, Kohler G, Muller U, et al. Defective nitric oxide effector functions lead to extreme susceptibility of Trypanosoma cruzi-infected mice deficient in gamma interferon receptor or inducible nitric oxide synthase. Infect Immun 1998;66:1208-15.
27. Centurion-Lara A, Barrett L, Van Voorhis WC. Quantitation of parasitemia by competitive polymerase chain reaction amplification of parasite kDNA minicircles during chronic infection with Trypanosoma cruzi. J Infect Dis 1994;170:1334-9.
28. Sawyer L, Mababangloob R, Propst M, et al. Inactivation of blood-borne pathogens in apheresis plasma and platelets using the INTERCEPT Blood System. Hematol J 2005;90:242.
29. Janetzko K, Cazenave JP, Kluter H, et al. Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set. Transfusion 2005;45:1443-52.
30. Guide to the preparation, use and quality assurance of blood components. 12th ed. Strasbourg: Council of Europe Publishing; 2006.
31. Barea L, Cañavate C, Flores M, et al. Seroprevalence of anti-Trypanosoma cruzi antibodies in blood donors coming from Chagas disease endemic counties. Vox Sang 2004.